Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.
Pharmaceutical professionals should have a “wide-ranging” debate on how IP can be tailored in the face of “major changes” to the industry, including the possibility of “prolonged exclusivity” for certain medicines, according to a report.
Pfizer and Mylan have agreed to settle litigation related to arthritis treatment Celebrex (celecoxib), Mylan announced today, June 2.
A pharmaceutical company in Turkey has run into trouble after attempting to register the Turkish word for ‘pharmacist’ as a trademark.
Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.
Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked.
US-based drug company Acura and Novartis’s generic arm Sandoz have settled their patent infringement dispute related to an abuse-deterrent formulation of the painkiller Aversion (oxycodone).
Generics (UK) Limited, the UK arm of Mylan, has succeeded in invalidating a patent held by Hungarian pharmaceutical company Richter Gedeon at the English High Court.
Medical device rivals Medtronic and Edwards Lifesciences have agreed to settle all patent litigation, including cases related to transcatheter heart valves.
The United Nations Development Programme has released a guidebook for low- to middle- income countries on how to increase access to essential health technologies and HIV treatments by using competition law and policy.